Clinical Trials Logo

Filter by:
NCT ID: NCT00627055 Completed - HIV Infections Clinical Trials

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

Start date: May 2008
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety at 48 weeks between LPV/r monotherapy and 2 NRTIs + LPV/r therapy in patients failing a standard NNRTI-based treatment regimen. Also, to evaluate the short-term 24-week efficacy and safety of Lopinavir/ritonavir (LPV/r) monotherapy and 2 NRTIs+LPV/r therapy in patients failing a standard NNRTI-based treatment regimen as an interim analyses when 50% of the patients in each arm have reached 24 weeks after randomization. Last, to define risk factors for monotherapy failure in HIV-treated individuals Hypothesis. The rate of virologic suppression is not inferior in the monotherapy arm.

NCT ID: NCT00626301 Completed - HIV Infections Clinical Trials

Lopinavir/Ritonavir Monotherapy in Children

Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy (clinical, immunological, virological outcome), pharmacokinetics and safety of lopinavir/ritonavir (LPV/r) monotherapy maintenance in Thai children after viral load suppression with double boosted protease inhibitors (PIs).

NCT ID: NCT00623597 Completed - HIV Infections Clinical Trials

A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.

Start date: June 2008
Phase: Phase 2
Study type: Interventional

This single arm study will assess the pharmacokinetics, safety and activity of saquinavir (Invirase hard gel capsules, film coated tablets or opened capsules) boosted by combination with ritonavir, in HIV-1 infected infants and children between the ages of 4 months and 6 years. Patients will commence treatment with saquinavir 50mg/kg bid plus ritonavir 2.5mg/kg or 3.0mg/kg (dependent on body weight), and a background antiretroviral regimen. If drug exposures are found to be dissimilar to those previously seen in older children and adults, or are associated with toxicities, subsequent dose adjustments will be made. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.

NCT ID: NCT00622206 Completed - HIV Infections Clinical Trials

Pharmacokinetics of Low Dose Ritonavir

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Compare the Pharmacokinetics of ritonavir and saquinavir(using either Saquinavir /Ritonavir 1500/100 mg or 1500/50 mg) Evaluate short term tolerability, safety and toxicity Evaluate if there is any relation between RTV concentration levels and boosting effect

NCT ID: NCT00621764 Completed - Hepatitis A Clinical Trials

Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

Start date: March 2008
Phase: Phase 2
Study type: Interventional

Safety: To describe the safety profiles following vaccination. Immunogenicity: To describe the immune response after a single dose of vaccine.

NCT ID: NCT00621504 Completed - Bacterial Pneumonia Clinical Trials

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

CAP
Start date: January 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia

NCT ID: NCT00621166 Completed - HIV Infections Clinical Trials

Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women

Start date: June 2008
Phase: Phase 2
Study type: Interventional

To determine the pharmacokinetic profile of generic lopinavir/ritonavir tablets To investigate the possible influence of pregnancy and duration of pregnancy To determine the antiviral activity and safety of generic lopinavir/ritonavir® Compare pharmacokinetics parameters before and after pregnancy.

NCT ID: NCT00621140 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Start date: February 2008
Phase: Phase 3
Study type: Interventional

To investigate efficacy, safety and tolerability of BI 1356 versus placebo

NCT ID: NCT00617981 Completed - Clinical trials for Hepatocellular Carcinoma

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Start date: May 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with radiofrequency ablation (RFA).

NCT ID: NCT00615303 Completed - Colonoscopy Clinical Trials

The Effectiveness of Simethicone In Improving Visibility During Colonoscopy

Start date: December 2006
Phase: Phase 4
Study type: Interventional

Sodium phosphate is one of the bowel preparation regimens for colonoscopy. However, intraluminal gas can impair visibility during the examination. Simethicone is medication that works by reducing the surface tension of air bubbles. We aimed to evaluate the effect of simethicone in enhancing visibility and efficacy during colonoscopy.